Background: Transient episodes of HIV type-1 viraemia are frequently observed in patients on suppressive combination antiretroviral therapy (cART). We studied the effect of such episodes and of treatment interruptions on clinical outcome and immunological response. Methods: A total of 3,321 patients from the ATHENA cohort had virological suppression (HIV type-1 RNA<50 copies/ml) after 24 weeks of cART. The association between subsequent episodes of treatment interruptions, viral suppression, low-level (50-400 copies/ml) and high-level (>400 copies/ml) viraemia and the outcomes death, AIDS or immunological response (CD4 + T-cell count increase ≥50% from 24 weeks) was studied with Poisson regression models, including either time-updated cumulative follow-up, time spent per type of episode or modelling episodes as binary status indicators. In a majority of HIV type-1 (HIV-1)-infected patients, treatment with combination antiretroviral therapy (cART) results in sustained suppression of plasma HIV-1 RNA levels to below the limits of quantification. However, during follow-up, many patients who have previously achieved viral suppression have measurable but transient episodes of viraemia whilst on cART [1] [2] [3] [4] [5] [6] . In addition, many patients have treatment interruptions, for example, as a result of drug-related toxicities or poor adherence [7, 8] .
High-level viraemia -plasma RNA levels typically >400 copies/ml -during treatment with cART has been shown to be related to a less favourable immune response, to development of opportunistic diseases and to progression to death, even after adjustment for CD4 + T-cell counts [9] [10] [11] . Low-level short-term viraemia reportedly has a limited effect on virological and immunological responses and on the development of drug resistance [5, 12] . Persistent low-level viraemia or frequent episodes of low-level viraemia, however, Introduction have been associated with virological failure and the emergence of drug resistance [13, 14] . These findings suggest that the magnitude, the duration and the frequency of viraemia are important factors related with clinical outcome. In addition, treatment interruptions might be expected to affect clinical outcome, as they lead to decreasing CD4 + T-cell counts and increasing viral load [9, 15, 16] .
Original article
Previously, we studied the prevalence and characteristics of episodes of transient viraemia in a large observational cohort of patients who had achieved sustained virological suppression after starting cART [6] . In the present study, we expand these analyses and investigate the effect of episodes of viraemia and therapy interruptions on both immunological response and longer-term clinical outcome, irrespective of the underlying cause of such episodes.
Methods
Patients included in this study were selected from the ATHENA national observational cohort in the Netherlands, which by February 2008 consisted of 14,536 patients [17] . HIV-1-infected patients were eligible for inclusion if they had started cART whilst being antiretroviral therapy-naive, were ≥13 years of age at start of cART and were treated continuously for at least 24 weeks. At 24 weeks after starting cART, CD4 + T-cell counts and HIV-1 RNA plasma levels were determined by taking the value closest to 24 weeks measured between 12 and 36 weeks after start of cART. The analysis was restricted to patients with a 24-week CD4 + T-cell count measurement available and a corresponding viral load <50 copies/ml, which was the lower limit of quantification of the most commonly used assays. Disease stage was defined as the most serious CDCclassified event recorded up to 24 weeks after start of cART [18] . CD4 + T-cell count and viral load at start of cART were determined by taking the value closest to start of cART measured within 12 weeks prior to start.
Treatment interruptions and episodes of viral suppression or viraemia were considered from 24 weeks after start of cART onwards. A treatment interruption (or treatment discontinuation in case therapy was not restarted) was defined as an episode of any duration without antiretroviral drugs. Patients with an interruption of >1 year were censored at 1 year after the start of the interruption. During treatment (not during treatment interruptions), episodes of viraemia were defined as starting when the viral load increased to a level >50 copies/ml and ending when it returned to <50 copies/ml. Analogously, an episode of viral suppression started with a viral load <50 copies/ml and ended when it increased to >50 copies/ml. Episodes of viraemia were subdivided into low-level viraemia if the median viral load during the episode remained between 50 and 400 copies/ml or high-level viraemia if the median viral load was >400 copies/ml. The cutoff of 400 copies/ml was chosen such that one-third of the RNA measurements exceeding 50 copies/ml were >400 copies/ml [6] . In a sensitivity analysis, the threshold of high-level viraemia was changed to 1,000 instead of 400 copies/ ml. The duration of an episode was calculated as the time between the first and the last RNA measurements defining the episode. Note that episodes of viral suppression and viraemia were only defined when patients were on cART as there were no viral load measurements during 33% of treatment interruptions.
Three different end points were considered in our study, including death from any cause, AIDS and immunological response. The latter was defined as a CD4 + T-cell count increase of 50% or more compared with the value at 24 weeks, which was chosen such that the median event time was comparable to the median duration of episodes of viral suppression. In a sensitivity analysis, an alternative definition of immunological response was used, namely an increase of ≥150 cells/mm 3 from 24 weeks. Patients who did not reach the end point before the end of follow-up were censored at their last follow-up visit. Of the 88 patients who died, 13 (15%) discontinued treatment in the 3 months before their death. As in these cases, the discontinuation of treatment could possibly be attributed to the expectation of death in the near future; treatment discontinuations within 3 months before the date of death were not considered as such, but rather as a continuation of the episode of viraemia or suppression preceding the discontinuation.
The association between episodes of viraemia and treatment interruptions and each of the three end points were studied using Poisson regression models, in which each patient's follow-up time was divided into 1-week intervals. All models were adjusted for age, gender, transmission category, country of birth, disease stage and CD4 + T-cell count at 24 weeks and viral load at start of cART. In the first set of models, the effect of viraemia and interruptions on outcome was studied by including the cumulative follow-up time spent in each type of episode at the start of each time interval as a time-updated variable ('cumulative effect model'). In a second set of models, we studied the relation between outcome and the most recent episode of viraemia or interruption. In these models, the type of episode at the start of each time interval was included as a timeupdated binary status indicator, distinguishing short (<3 months) or long (≥3 months) episodes of viraemia and treatment interruptions ('immediate effect model'). A series of sensitivity analyses were performed to assess the robustness of the Poisson regression models. All analyses were performed with SAS software (version 9.1.3; SAS Institute, Inc., Cary, NC, USA).
Results
The total population consisted of 3,321 patients with a total follow-up of 11,165 person-years (Table 1 ). The majority of the patients were men (2,571 patients, 77.4%), originated from the Netherlands (1,775, 53.4%) and were infected via homosexual (1,728, 52.0%) or heterosexual (1,232, 37.1%) contact. In total, 88 patients died, 111 progressed to AIDS and 2,019 patients had a CD4 + T-cell count increase of ≥50% after 24 weeks of cART.
Of the 3,321 patients, 511 (15.4%) interrupted cART at least once, 1,138 (34.3%) patients experienced at least one episode of viraemia and 389 (11.7%) patients had at least one episode of high-level viraemia. Of the patients with therapy interruptions, 184 (36.0%) experienced at least one episode of high-level viraemia, which was more often (P<0.001) than in patients without interruptions, of whom 205 (7.3%) experienced high-level viraemia. During follow-up, there were 4,940 episodes of viral suppression, 1,284 episodes of low-level viraemia, 531 episodes of high-level viraemia and 654 episodes of treatment interruption. The incidence rates of viraemia and treatment interruptions were highest in the first 2 years after 24 weeks of cART ( Figure 1 ). Thereafter, the incidence of high-level viraemia and treatment interruptions decreased (P<0.02), whereas the incidence of low-level viraemia was stable at approximately 9-11 per 100 person-years. Incidence rates of episodes of viraemia were approximately 20% lower when only considering patients without treatment interruptions.
The median duration of episodes was 17. than 3 months and 927 (72.2%) were shorter than 4 months. In total, 1,014 (79.0%) episodes of low-level viraemia consisted of one viral load measurement, 167 (13.0%) consisted of two measurements, 57 (4.4%) of three and 46 (3.6%) of four or more measurements. Of the 531 episodes of high-level viraemia, 155 (29.2%), 214 (40.3%) and 286 (53.8%) were shorter than 2, 3 and 4 months, respectively; 251 (47.3%) episodes consisted of one RNA measurement, 130 (24.5%) consisted of two, 51 (9.6%) of three and 99 (18.6%) consisted of four or more RNA measurements. Of the 654 episodes of treatment interruption, 320 (48.9%) were shorter than 3 months, 271 (41.4%) were shorter than 2 months and 202 (30.9%) were shorter than 1 month. The median time between viral load measurements was 3.4 (IQR 2.8-4.4) months.
Relative risks (RRs) for death, AIDS and a CD4 + T-cell increase ≥50% from 24 weeks after start of cART onwards are shown in Table 2 . Compared with episodes of viral suppression, a longer duration -relative to the total follow-up time -of treatment interruption was associated with progression to AIDS and a lower probability of having an immunological response. Also, spending more follow-up time in high-level viraemia was associated with a lower probability of immunological response. Episodes of low-level viraemia did not show such an association. Using the fraction of follow-up time in each type of episode instead of cumulative absolute follow-up time yielded similar associations between outcome and episodes of treatment interruption and viraemia (SZ et al., data not shown).
In the models that included long-and short-term episodes of viraemia and therapy interruption as timeupdated binary status indicator variables, the effect of short-and long-term episodes could not be estimated in the models with outcome death or outcome AIDS because of the small number of events in our study. Again, treatment interruptions and episodes of highlevel viraemia were associated with a higher risk of death or AIDS and an impaired immunological restoration. Episodes of low-level viraemia longer than 3 months were associated with a better immunological response (RR 1.93, 95% confidence interval [CI] 1.41-2.65), whereas episodes shorter than 3 months were not (RR 0.73, 95% CI 0.53-1.02). Similar results were obtained when immunological response was defined as were associated with a lower probability of immunological response. Viral load at start of cART was not significantly associated with outcome in any of the models and we decided to leave it out from the models.
To assess to what extent the model results depended on the definition of therapy interruptions, the models with an outcome of death or AIDS were repeated 3×, treating therapy interruptions with duration shorter than 1, 2 or 3 months as a continuation of the preceding episode in each respective analysis. The effect of excluding short-term interruptions appeared to be limited. The largest effects were observed when interruptions shorter than 3 months were discarded: RR associated with treatment interruptions changed by a maximum of 15%, but remained well within the 95% CI. We also assessed to what extent the model results depended on the way treatment discontinuations prior to death were dealt with. The threshold below which treatment discontinuations were regarded as a continuation of the episode of viraemia or suppression preceding the discontinuation was varied between 0 and 6 months (3 months in the main model). In this case, the RR associated with treatment interruptions in the immediate effect model was 3.7× higher than in the main analysis when all treatment discontinuations prior to death were regarded as such (0-month limit) and 0.51× smaller when treatment discontinuations shorter than 6 months were not taken into account as discontinuations.
We also investigated the effect of changing the threshold between low-level and high-level viraemia from 400 to 1,000 copies/ml. For the models with end points death and AIDS, the RR associated with high-level viraemia increased and became significantly (P=0.02) associated with outcome in the immediate effect models, that is, 3.53 (95% CI 1.26-9.87) for end point death and 3.00 (95% CI 1.19-7.55) for end point AIDS. The favourable association between longterm low-level viraemia and immunological response was attenuated (RR 1.62, 95% CI 1.20-2.19).
Because a large proportion of episodes of low-level and high-level viraemia consisted of one single viral load measurement, an analysis was performed in which the duration of such episodes was limited to a maximum of 3 weeks, which is the estimated duration of transient episodes of viraemia [4] . In this case, the association between long-term episodes of low-level viraemia and immunological response disappeared (RR 1.36, 95% CI 0.88-2.10), whereas short-term low-level viraemia became associated with a less favourable immunological response (RR 0.58, 95% CI 0.35-0.96; P=0.03).
When log-transformed CD4 + T-cell counts were included as a time-updated variable in both the cumulative and the immediate effect models, the effect of treatment interruptions and high-level viraemia on end point death and AIDS was attenuated. However, a residual effect of interruptions on progression to AIDS remained in both the immediate effect model (RR 4.07, 95% CI 2.06-8.05) and in the cumulative effect model (RR 4.58, 95% CI 2.13-9.83). When including time-updated viral load in addition to adjustment for the most recent episode of viraemia or treatment interruption, the immediate and cumulative effect of interruptions on progression to AIDS was attenuated further to RRs of 3.45 (95% CI 1.47-8.10) and 3.75 (95% CI 1.60-8.78), respectively.
When considering outcome immunological response, 283 (59.8%) of 473 patients who had at least one episode of low-level viraemia changed treatment at least once, which was more often (P<0.001) than amongst patients without low-level viraemia, of whom 948 (33.3%) changed treatment. For 230 (18.7%) of the 1,231 patients who changed treatment, the treatment change was followed by an episode of low-level viraemia after a median of 3.9 (IQR 0.2-10.8) months. Conversely, amongst the patients with an episode of low-level viraemia, 211 (44.6%) had a treatment change after a median of 0.5 (IQR 0.0-6.9) months. When the number of treatment changes was included as a time-updated variable, the first treatment change was associated with a more favourable immunological response (RR 1.15, 95% CI 1.03-1.29) compared with no change, whereas two or more changes were not associated with outcome (RR 0.97, 95% CI 0.83-1.14). Treatment changes were not associated with progression to death or AIDS.
Discussion
Our analysis showed that episodes of transient viraemia and treatment interruptions were a common phenomenon in a group of patients achieving initial virological suppression on cART. In general, treatment interruptions and episodes of high-level viraemia were associated with a greater risk of progression to death and AIDS and a less favourable CD4 + T-cell response, whereas the effect of low-level viraemia on outcome appeared to be limited.
Our study confirmed previous findings that treatment interruptions were associated with an increased risk of opportunistic infections [9, 19] . No significant association of interruptions with progression to death from any cause was observed, but this was probably because of the scarcity of events. It has been shown that therapy interruptions with a duration of a few weeks are not associated with a worse outcome [20] . In our study, however, the majority of treatment interruptions were longer than 2 months and, consequently, results did not change to a great extent when short-term interruptions were left out of the analysis. The effect of therapy interruptions on outcome was largely explained by their effect on viral load and CD4 + T-cell counts, as the effect of interruptions was attenuated after adjustment for time-updated viral load and CD4 + T-cell count [9, 16, 19] . The differences in the effect of high-level and lowlevel viraemia on clinical outcome can be explained by different underlying biological mechanisms. Low-level viraemia might, at least partially, be caused by random biological and statistical variations or release of virus from latent reservoirs, whereas high-level viraemia most probably represents ongoing virus replication indicative of therapy failure or inadequate adherence [5, 6, [21] [22] [23] [24] . Unfortunately, no data on adherence were available. However, in our analysis, we aimed to examine the effect of viraemia on outcome irrespective of the underlying cause; hence, data on adherence were not necessary, as the effect of inadequate adherence on clinical outcome was mediated by its effect on viral suppression and the occurrence of episodes of viraemia.
Long-term episodes of low-level viraemia appeared to be associated with a more favourable CD4 + T-cell response compared with episodes of viral suppression [3, 25] . A similar observation was made by another cohort that found that patients with infrequent lowlevel viraemia between 50 and 1,000 copies/ml had a higher CD4 + T-cell gain than patients with sustained virological suppression [25] . The mechanism behind this phenomenon is unknown, but it has been suggested that higher CD4 + T-cell gains provide a larger pool of uninfected cells and could thus be driving bursts of viral replication rather than being their consequence [25] . Treatment changes might also play a role because immunological response appeared to be better in patients with one treatment change and treatment changes were more often observed in patients with episodes of low-level viraemia. A treatment change possibly leads to a higher CD4 + T-cell gain comparable to the rapid increase observed in the first months after starting cART [26] . A causal relationship between treatment changes and the occurrence of episodes of low-level viraemia could, however, not be established. In sensitivity analyses, the favourable association between low-level viraemia and immunological response was attenuated or even disappeared when the definition of the duration of episodes of lowlevel viraemia was varied, or when episodes of lowlevel viraemia were defined as episodes with viral load values between 50 and 1,000 copies/ml. Short-term episodes of low-level viraemia were not associated or were adversely associated with CD4 + T-cell response depending on the definition of their duration; therefore, the associations found might be an artefact of the data and the definition of episodes.
Our study confirms previous findings that older age and male gender were related to an impaired immunological response [26] . The smaller probability of having a CD4 + T-cell count increase of ≥50% for patients with 24-week CD4 + T-cell counts >500 cells/mm 3 was most probably caused by a ceiling effect. The model with the end point death showed that patients of western origin had a slightly higher probability of progression to death than patients from sub-Saharan Africa and other regions. As this association was not observed in the models with outcome AIDS, it might be attributable to non-HIV-1-related causes of death. Although episodes of low-level viraemia were not associated with progression to death from all causes or AIDS, they might be associated with progression to non-AIDS end points such as major cardiovascular, renal or hepatic diseases and death related to such diseases. These events have been shown to be related to the level of immunodeficiency and to uncontrolled HIV-1 replication, even at high CD4 + T-cell counts [9, [27] [28] [29] . In addition, markers of inflammation and coagulation are tightly correlated with plasma RNA levels and are associated with an increased risk of cardiovascular events and all cause mortality [30] .
Episodes of viraemia might lead to onward transmission of HIV-1 to uninfected individuals, however, the probability of transmission is related to plasma RNA levels and is expected to be small for patients with viral load levels <1,000 copies/ml [31, 32] . Moreover, it has been estimated that at most, 10% of new infections amongst homosexual men in the Netherlands were from men aware of their HIV-1 infection [33] . Hence, patients with low-level viraemia, and probably also patients with high-level viraemia or treatment interruptions, are currently not expected to contribute to a great extent to the HIV-1 epidemic in the Netherlands. Recently, a Swiss consensus statement suggested that successfully treated patients under certain conditions are sexually non-infectious [34] . It has been shown that if this leads to an increase in unprotected sexual contacts there is a potential for substantial increases in HIV-1 transmission [32] . These increases could be exacerbated by the occurrence of episodes of viraemia, which according to our study are not a rare phenomenon in successfully treated patients even 5 years after starting cART.
Our study probably overestimated the duration of episodes of low-level viraemia. The median time between viral load measurements was 3-4 months, which is much longer than the estimated duration of 21 days for an episode of low-level transient viraemia [4] . As a result, episodes of low-level viraemia might have been missed, but the effect of this on our models is expected to be limited as low-level viraemia was not or was only marginally associated with clinical outcome. Episodes of high-level viraemia were less likely to be missed as they had a longer duration and were frequently associated with clinical events [6] .
A limitation of our study was the relatively short median follow-up time compared with the duration of chronic HIV-1 infection in the era of cART, although >25% of the patients had at least 5 years of follow-up, therefore, our study could only detect short-term effects of viraemia and longer-term effects remained undisclosed. Another limitation was that the number of clinical events was low, yielding wide CIs on estimated parameters. For this same reason, we could not distinguish between different causes of death. Also, as the data were of an observational nature, the results found in our analyses can only be interpreted as associations and not as causal relations.
In conclusion, we showed that treatment interruptions and episodes of high-level viraemia were associated with a worse clinical prognosis and a worse immunological response. Low-level viraemia, however, was generally not associated with outcome. The effect of viraemia and treatment interruptions was largely mediated by CD4 + T-cell counts.
